Age-related Macular Degeneration (AMD) Market Size & Share, by Type (Wet AMD, Dry AMD); Application (Hospital, Clinic, Research Institute) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5833
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024- 2036

Age-related Macular Degeneration Market size is expected to reach USD 105 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of age-related macular degeneration was USD 8 Billion. Age-related macular degeneration is a frequent disorder among the elderly population that progresses over time. The prevalence of age-related macular degeneration is on the rise worldwide, partly due to the expanding elderly population. Therapeutics to address the disease are thus in great demand. Taking advantage of this chance, pharmaceutical companies are concentrating on developing medications to cure age-related macular degeneration. At this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of persons sixty years of age and older will quadruple globally by 2050. It is anticipated that between 2020 and 2050, the number of people 80 years of age or older will triple, reaching 426 million.

New therapeutic techniques, such as gene therapy and long-acting anti-VEGF injections, provide prospects for better patient convenience and better results. Advances in diagnostic imaging methods such as optical coherence tomography allow for earlier detection and intervention, which in turn improves therapy efficacy.

AMD Therapeutics Market
Get more information on this report: Request Free Sample PDF

Age Related Macular Degeneration Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Burden of AMD - The worldwide burden of AMD proceeds to rise at an exceptional speed as the worldwide populace develops and the socioeconomics reflects a larger part of more seasoned individuals. As of the World Health Organization, there are as of now around 1.1 billion tobacco clients within the world, with that figure likely to twofold by 2050 on the off chance that current patterns proceed. As a result, cigarette utilization is thought to be a major donor to the worldwide increment in AMD predominance. 
  • Government Initiatives - Public health initiatives pointed toward bringing issues to light about AMD and advancing early identification, for example, those drove by groups like Fighting Blindness Canada in Canada, energize opportune treatment commencement and extensive sickness the board. These initiatives are intended to reach more people in need of treatment, which is likely to increase demand on the market.


  • Lack of Effective Treatments for Dry AMD - There is currently no cure for AMD and there are only a few approved treatments available for the wet form of the disease. Dry AMD is the more common form, accounting for about 85% of cases but there are no approved drugs specifically for dry AMD. While some treatments for wet AMD can be used off-label for dry AMD they are not as effective and can be expensive.
  • High Cost of Treatments is Expected to Hinder the Market Growth in the Forecast Period
  • Complexities Associated with the Development of New treatments are estimated to hinder market growth in the upcoming period

Age-related Macular Degeneration Market: Key Insights

Base Year


Forecast Year

2024 - 2036



Base Year Market Size

~USD 8 Billion

Forecast Year Market Size

~USD 105 Billion

Regional Synopsis

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Age-related Macular Degeneration Segmentation

Type (Wet AMD, Dry AMD)

In terms of type, the wet age-related macular degeneration market is anticipated to hold the highest CAGR of 80% during forecast period 2024-2036. Age-related macular degeneration is the beginning of the normal development of blood vessels below the retina. As AMD is the most common cause of significant loss of vision in people over the age of 50, the growing population around the world is creating a high level of demand in the market for wet age-related macular degeneration. In the next few years, East and Southeast Asia are expected to have the greatest increase of about 312 million people as indicated in the United Nations World Ageing Report 2019. In addition, approximately 200 million people over the age of 65 live in North America and Europe in 2019. These figures demonstrate that, all over the world, there will be a strong demand for therapies to treat age related macular degeneration in the future.

Application (Hospital, Clinic, Research Institute)

In terms of application, the hospital segment in the global age-related macular degeneration market is set to hold the highest CAGR of 60% by the end of 2036. The increase in the incidence of age-related macular degeneration and hospitalization for treatment may account for this dominant position. Various medicines, such as Lucentis, Eylea, and Beovu, administered intravenously under the supervision of experienced physicians in hospitals, are used to treat most patients. Therefore, hospital visits are expected to increase as a result of the growing demand for AMD treatment and this is likely to drive the market.

Our in-depth analysis of the global market includes the following segments:


  • Wet AMD
  • Dry AMD


  • Hospital
  • Clinic
  • Research Institute

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Age-related Macular Degeneration Industry - Regional Synopsis

North American Market Forecasts

The age-related macular degeneration (AMD) market in the North America region is set to hold the largest market share of 35% by the end of 2036. The rising interest of critical market players and expanded investigation and improvement exercises are a few of the powers affecting age-related macular degeneration advertise development within the North American region. Moreover, the American Macular Degeneration Foundation within the Joined together States spread this data to caution AMD patients and eye care experts approximately the potential danger. Around the world, progressed AMD could be an essential cause of changeless visual deficiency and visual disability. As a result, the advertising is developing as AMD's load develops. Further, Wet age-related macular degeneration is one of the driving causes of visual misfortune in grown-ups over 65, concurring to the Canadian Ophthalmological Society. One of its considerations, discharged in 2019, anticipated that by 2032, at slightest one out of every four Canadians would have age-related macular degeneration. As a result of the previously mentioned components, the showcase within the locale is anticipated to be created altogether over the estimated period. 

APAC Market Statistics

The age-related macular degeneration market in the Asia Pacific region is anticipated to hold a substantial market share during the projected period. Due to a lack of availability and the high cost of drugs, sales of exudatory AMD medicines in Asia Pacific are not yet significant. Moreover, there are relatively few companies involved in the marketing and research of exudate AMD medicines in Asia Pacific. In expansion, the locale accounts for more than a third of all age-related macular degeneration cases recorded all-inclusive hence request for damp AMD medicines is anticipated to extend drastically in the future for a long time. 

Research Nester
AMD Therapeutics Market SIZE
Get more information on this report: Request Free Sample PDF

Companies Dominating the Age-related Macular Degeneration Landscape

    • DaVinci, Magnifying America
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Freedom Scientific
    • LVI Low Vision International
    • NuEyes
    • Canadian Assistive Technologies
    • Merlin Ultra
    • HumanWare
    • Biogen
    • Samsung Bioepis
    •  Eschenbach Optik GmbH


In The News

  • Mosaic Biosciences and Ocular Therapeutix entered into a investigate collaboration for the advancement of a medicate to treat patients with dry age-related macular degeneration. This collaboration fortifies the company's R&D portfolio and offers a tall development opportunity for the company. 
  • Aldeyra Therapeutics announced the advancement of its RASP modulator platform, including the anticipated submission of an IND application for the investigational RASP modulator ADX248 for the Phase ADX629 1/2 clinical trial in patients with dry form of age-related macular degeneration and dark adaptation deficit.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5833
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of AMD and increasing geriatric population are some of the major factors anticipated to drive the growth of the age-related macular degeneration market.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are of Canadian Assistive Technologies, Merlin Ultra, HumanWare, Biogen, Samsung Bioepis, Eschenbach Optik GmbH, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Age-related Macular Degeneration Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying